Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Taro Pharmaceuticals USA"
Count: 69
Selected: 0
NCT IDTitle
NCT05282771A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
NCT05148689A Study Comparing Oxymetazoline 1% Cream to RHOFADE
NCT04883736A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris
NCT04883593A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
NCT04797793A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
NCT04724473A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris
NCT04358770Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream
NCT02340169Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis
NCT04321070Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
NCT04134273Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
NCT03645499An Open-Label Study to Assess Safety
NCT01876550A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.
NCT03880357To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis
NCT03689010To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
NCT02933879Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study
NCT02933502Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
NCT02618759Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
NCT02932891An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
NCT02601469Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
NCT02595073Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
NCT02595008Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
NCT02933866Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
NCT02933528Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
NCT02932878An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
NCT02932462Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis
NCT02413229A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
NCT02935036Efficacy Study in Patients With Acne Vulgaris.
NCT02343627Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail
NCT02335255Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis
NCT03433378To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris
NCT03427554To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris
NCT03257943A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%
NCT02578043A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris
NCT01206387Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
NCT02132260Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis
NCT01769235Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris
NCT01580878Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis
NCT03132194Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
NCT03094403To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel
NCT02929719Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
NCT02709902Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
NCT02595034A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris
NCT02411955A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris
NCT02411942Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris
NCT01742637Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris
NCT00752973Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
NCT01018134Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study
NCT00927472Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
NCT01206660Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
NCT00963508Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice